The GOLD Study: G8 in OLDer Patients

Launched by ISTITUTO ONCOLOGICO VENETO IRCCS · Feb 23, 2018

Keywords

ClinConnect Summary

The GOLD Study, also known as the G8 in OLDer Patients trial, is focusing on improving the treatment of older patients with metastatic colorectal cancer, which is a serious form of cancer that has spread beyond the original site. Because older adults often have different health needs and challenges, doctors need better ways to decide on the most suitable treatments for them. This study is looking at a simple tool called the G8 assessment, which helps doctors evaluate an older patient’s overall health and well-being by checking factors like nutrition, mobility, and mental health. The goal is to see if using the G8 tool can help identify patients who might need more thorough evaluations before starting treatment.

To participate in this study, individuals must be at least 70 years old and have been newly diagnosed with metastatic colorectal cancer that has not yet been treated. They will need to provide consent for their participation. Throughout the trial, researchers will gather information on how well the G8 assessment works in predicting treatment outcomes and side effects in this patient group. This study aims to make sure that older patients receive the best possible care tailored to their specific needs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New diagnosis of metastatic colorectal cancer, untreated in the metastatic setting
• • Age ≥ 70 years
• • Availability of clinical data
• • Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations